Sign In
Buy GLPG
$27.38
+0.0650 (+0.238%)
At Close: Jun 03, 2026
Galapagos NV (GLPG) Q1 2025 Earnings Call Transcript
11:34am, Thursday, 24'th Apr 2025
Galapagos NV (NASDAQ:GLPG ) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Paul Stoffels - Chair, Chief Executive Officer Thad Huston - Chief Operating, Chief Financia
Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts
04:01pm, Wednesday, 23'rd Apr 2025
First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal developme
Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025
01:30am, Tuesday, 15'th Apr 2025
Mechelen, Belgium; April 15, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient
Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders' Meeting
04:01pm, Thursday, 27'th Mar 2025
Mechelen, Belgium; March 27, 2025, 21:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2024 and announces its Annual Sh
Galapagos to Present at Upcoming Investor Conferences
04:01pm, Monday, 24'th Feb 2025
Mechelen, Belgium; February 24, 2025, 22:01 CET – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and
Disount To Net Cash For A Promising CAR-T Company
07:13am, Thursday, 20'th Feb 2025
Galapagos NV announced a strategic split with Gilead Sciences, creating 'New Galapagos' and 'SpinCo', aiming to unlock shareholder value and reduce staffing by 40%. 'New Galapagos' will focus on cell
Galapagos receives transparency notification and 13D filing from Tang Capital
04:01pm, Monday, 17'th Feb 2025
Mechelen, Belgium; February 17, 2025, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification and 13D filing from Tang Capital.
Galapagos NV (GLPG) Q4 2024 Earnings Call Transcript
01:26pm, Thursday, 13'th Feb 2025
Galapagos NV (NASDAQ:GLPG ) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Sri Ramaswami - Senior Vice President and Global Head of Corporate Affairs & Investor Rel
Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update
04:01pm, Wednesday, 12'th Feb 2025
Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein
Galapagos (GLPG) Loses -21.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Wednesday, 05'th Feb 2025
Galapagos (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates
Galapagos To Spin Off Innovative Medicines Business
12:08pm, Tuesday, 21'st Jan 2025
Deal Overview
Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities
01:30am, Wednesday, 08'th Jan 2025
Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions
Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference
04:01pm, Tuesday, 07'th Jan 2025
Mechelen, Belgium; January 7, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Company will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Wednesday,
Mechelen, Belgium; December 7, 2024, 18:30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced additional data from the ongoing Phase 1/2 ATALANTA-1 study of its CD19 CAR T-cell therapy, GLPG5
Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024
04:01pm, Tuesday, 05'th Nov 2024
Mechelen, Belgium; November 5, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new data from its CAR T- and TCR T-cell therapy pipeline at the 66 th Americ
